Literature DB >> 8554125

Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head.

C A Staley1, J E Lee, K R Cleary, J L Abbruzzese, C J Fenoglio, T A Rich, D B Evans.   

Abstract

BACKGROUND: Local recurrence in the bed of the resected pancreas is the most common site of tumor recurrence following a standard pancreaticoduodenectomy (PD) for adenocarcinoma of the pancreatic head. In an attempt to improve local and regional disease control and thereby enhance the quality and length of survival in patients undergoing potentially curative PD, we have used a protocol of preoperative multimodality therapy. PATIENTS AND METHODS: All patients were treated with external-beam radiation (30.0 or 50.4 Gy) and concomitant 5-fluorouracil (300 mg/m2 per day) prior to PD. Electron-beam intraoperative radiation therapy was given to the bed of the resected pancreas before reconstruction. Patients were assessed for recurrence by physical examination, chest roentgenography, and computed tomography scan performed at 3-month intervals following treatment.
RESULTS: Thirty-nine patients completed all therapy; 1 perioperative death occurred. Thirty-eight tumor recurrences have been documented in 29 patients at a median of 11 months from the date of diagnosis; 23 patients died of disease. The liver was the most frequent site of recurrence, and liver metastases were a component of treatment failure in 53% of patients. Isolated local or peritoneal recurrences were documented in only 4 patients (11%). The only significant clinical or pathologic variable predictive of local-regional recurrence was a previous laparotomy and intraoperative biopsy. The median survival of all 39 patients was 19 months, and the 4-year actuarial survival rate was 19%.
CONCLUSIONS: Preoperative chemoradiation, PD, and electron-beam intraoperative radiation therapy for adenocarcinoma of the pancreatic head have resulted in improved local-regional tumor control, with distant metastatic disease becoming the predominant site of tumor recurrence. Future treatment strategies should incorporate effective multimodality therapy for local-regional disease as demonstrated in this study. Major improvements in overall survival will likely await the development of systemic or regional therapy for liver metastases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8554125     DOI: 10.1016/S0002-9610(99)80085-3

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  38 in total

Review 1.  Adjuvant therapy in pancreatic cancer.

Authors:  P Ghaneh; J Slavin; R Sutton; M Hartley; J P Neoptolemos
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

Review 2.  Current and future strategies for combined-modality therapy in pancreatic cancer.

Authors:  Andrew H Ko; Margaret A Tempero
Journal:  Curr Oncol Rep       Date:  2002-05       Impact factor: 5.075

Review 3.  Preoperative chemoradiation for resectable and locally advanced adenocarcinoma of the pancreas.

Authors:  D B Evans
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

Review 4.  Current approaches and future strategies for pancreatic carcinoma.

Authors:  R A Wolff; P Chiao; R Lenzi; P W Pisters; J E Lee; N A Janjan; C H Crane; D B Evans; J L Abbruzzese
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

5.  Carcinoma of the Pancreas.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-06

6.  A decision model of therapy for potentially resectable pancreatic cancer.

Authors:  Jacob P VanHouten; Rebekah R White; Gretchen Purcell Jackson
Journal:  J Surg Res       Date:  2011-09-12       Impact factor: 2.192

7.  Advanced Pancreatic Adenocarcinoma: Complete Histological Response After Palliative Therapy with Gemcitabine and Cisplatin.

Authors:  A Alexander; A Rehders; R Riediger; M Schmitt; M Anlauf; W T Knoefel
Journal:  J Gastrointest Cancer       Date:  2012-09

8.  Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer.

Authors:  Charles C Hsu; Christopher L Wolfgang; Daniel A Laheru; Timothy M Pawlik; Michael J Swartz; Jordan M Winter; Raymond Robinson; Barish H Edil; Amol K Narang; Michael A Choti; Ralph H Hruban; John L Cameron; Richard D Schulick; Joseph M Herman
Journal:  J Gastrointest Surg       Date:  2012-02-07       Impact factor: 3.452

9.  Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ESPAC-1).

Authors:  J P Neoptolemos; P Baker; H Beger; K Link; P Pederzoli; C Bassi; C Dervenis; H Friess; M Büchler
Journal:  Int J Pancreatol       Date:  1997-04

10.  Effect of end-to-end invagination pancreaticojejunostomy with circle discontinuous U suture in pancreatic surgery.

Authors:  Xuewen Zhang; Wei Xuan; Tao Jiang; Degang Ji; Yongsheng Yang; Dan Zhang; Yingjun Xie; Zihui Meng; Jisheng Zhao
Journal:  Front Med China       Date:  2007-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.